Platelet Function in Patients With an Acute Coronary Syndrome (ATLANTIS-ACS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01992484|
Recruitment Status : Unknown
Verified November 2013 by Jolanta Siller-Matula, Medical University of Vienna.
Recruitment status was: Recruiting
First Posted : November 25, 2013
Last Update Posted : November 25, 2013
The aims of the study are to:
- explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome
- investigate whether a therapeutic window exist for novel platelet inhibitors
- investigate the incidence of adverse events under treatment with novel platelet inhibitors in the real life clinical scenario
- investigate the association between genetic polymorphisms, inflammation, platelet reactivity and clinical outcome
- investigate synergistic effects between aspirin and novel platelet inhibitors
|Condition or disease|
|Acute Coronary Syndrome (ACS)|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Association Between the Antiplatelet Drug Efficacy/Safety and Platelet Function in Patients Treated With Novel Platelet Inhibitors Due to an Acute Coronary Syndrome|
|Study Start Date :||August 2012|
|Estimated Primary Completion Date :||June 2015|
- Net clinical benefit. [ Time Frame: 1 year ]A composite of MACE and BARC=>2 bleedings.
- MACE and Major bleeding [ Time Frame: 1 year ]
MACE: the composite of stent thrombosis, cardiac death and myocardial infarction.
Major Bleeding: BARC =>2, TIMI major, GUSTO moderate-severe-life threatening.
- single endpoints of acute coronary syndrome, myocardial infarction, cardiac death, all-cause death, urgent vessel revascularization (PCI or CABG), stroke. [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01992484
|Contact: Jolanta M Siller-Matula, PD MD PhD||0043 1 firstname.lastname@example.org|
|Medical Univerity of Vienna, Department of Cardiology||Recruiting|
|Principal Investigator: Jolanta M Siller-Matula, PD MD PhD|
|Principal Investigator: Georg Delle-Karth, MD|